Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure

Journal of Nuclear Cardiology

Volumn 4, Issue 6, 1997, Pages 494-501

  Schaadt, Bente ^a,b   Kelbæk, Henning ^a  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anthracycline cardiotoxicity; Heart failure; Left ventricular ejection fraction; Radionuclide angiocardiography

Indexed keywords

EPIRUBICIN; RADIOISOTOPE;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG INDUCED DISEASE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCINTIANGIOGRAPHY; STATISTICAL ANALYSIS;

EID: 0031450801     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-3581(97)90007-6     Document Type: Article

References (22)

1. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981;305:139-53.
2. Kantrowitz NE, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984;27:195-200.
3. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.
4. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979;63:827-34.
5. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979;91:710-7.
6. Ganzina F. 4-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983;10:1-22.
7. Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985;3:818-26.
8. Dardir MD, Ferrans VJ, Mikhael YS, et al. Cardiac morphologic and functional changes induced by epirubicin chemotherapy. J Clin Oncol 1989;7:947-58.
9. Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990;8:1806-10.
10. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardio toxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-83.
11. Choi BW, Berger HJ, Schwartz PE, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 1983;106:638-43.
12. Palmeri SB, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986;58:607-13.
13. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 1987;82:1109-18.
14. European Organization for Research and Treatment of Cancer. A practical guide to EORTC studies. Brussels: The Organization; 1994. p. 107-36.
15. Gjørup T, Kelbask H, Vestergaard B, et al. Reproducibility in the analysis of multigated radionuclide studies of left ventricular ejection fraction. Invest Radiol 1989;24:104-9.
16. Kelbæk H, Gjørup T, Büllow K, et al. Observer variability of radionuclide left ventricular volume determination at rest and during exercise. Acta Radiol 1993;34:179-82.
17. Rozanski A, Berman DS. The efficacy of cardiovascular nuclear medicine exercise studies. Semin Nucl Med 1987;17:104-7.
18. Gjørap T, Kelbæk H, Vestergaard B, Munck O, Godtfredsen J. Prospective randomized double-blind study of radionuclide determination of left ventricular ejection fraction in acute myocardial infarction. Lancet 1986;1:583-5.
19. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of the left ventricular filling dynamics. Am Heart J 1989;118:92-8.
20. Cottin Y, Touzery C, Coudert B, et al. Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J 1995;73:61-4.
21. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324: 808-15.
22. Carrio I, Estorch M, Lopez-Pousa A. Assessing anthracycline cardiotoxicity in the 1990s. Eur J Nucl Med 1996;23:359-64.